Contributing to the promise of Surgical Oncology
17 March 2017
Researchers and clinicians from Melanoma Institute Australia (MIA) are meeting with more than 1,700 colleagues from around the world today at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium in Seattle, USA. The theme of the meeting is “discovering the promise of what’s possible” and invites attendees to learn about the exciting possibilities for improving oncologic outcomes for patients.
The conference provides surgical oncology leaders with an opportunity to share research and network to advance the field. Four of MIA’s current or former fellows are presenting their research to colleagues at the conference, in addition to several more in attendance.
MIA's 2016 Poche Surgical Fellow, Dr Kim Isaacs, is sharing her research at the conference. Most guidelines recommend that melanoma patients have a complete lymph node dissection after they have had a positive sentinel lymph node identified; however, this doesn’t always happen. Dr Isaacs’s research investigated the factors that influence a melanoma patient’s choice to have a complete lymph node dissection or not. This research will help determine why some patients are not going ahead with this potentially life-saving surgery.
Research fellow, Trine Schoenfeldt, from Denmark is presenting her MIA research that is looking at the ideal surgical management for patients who have melanoma metastases in the sentinel nodes located near their armpit (specifically the triangular intermuscular space). How to manage patients with these metastases is considered controversial for surgeons, so having scientific evidence about the best course of treatment will ensure the best care for patients.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.